-
Product Insights
Amyloid Cardiomyopathy - Drugs In Development, 2024
Empower your strategies with our Amyloid Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions. Amyloid cardiomyopathy (stiff heart syndrome) is a condition resulting in the death of part of the myocardium (heart muscle). It is associated with the systemic production and release of many amyloidogenic proteins, especially immunoglobulin light chain or transthyretin (TTR). The Amyloid Cardiomyopathy drugs in development market research report provide comprehensive information on the therapeutics under development for Amyloid Cardiomyopathy, complete with analysis...
-
Product Insights
Hyperinsulinemia - Drugs In Development, 2024
Empower your strategies with our Hyperinsulinemia – Drugs In Development, 2024 report and make more profitable business decisions. Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue, and frequent hunger. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes, and hypertension. Treatment includes insulin secretion inhibiting agents, diet,...
-
Product Insights
Non-Proliferative Diabetic Retinopathy (NPDR) - Drugs In Development, 2024
Empower your strategies with our Non-Proliferative Diabetic Retinopathy (NPDR) – Drugs In Development, 2024 report and make more profitable business decisions. Non-proliferative diabetic retinopathy (NPDR) is the early stage of the disease in which symptoms will be mild or nonexistent. In NPDR, the blood vessels in the retina are weakened. Tiny bulges in the blood vessels, called microaneurysms, may leak fluid into the retina. This leakage may lead to swelling of the macula. The Non-Proliferative Diabetic Retinopathy (NPDR) drugs in development...
-
Product Insights
Insulin Resistance - Drugs In Development, 2024
Empower your strategies with our Insulin Resistance – Drugs In Development, 2024 report and make more profitable business decisions. Insulin resistance (IR) is a condition in which the body's cells become resistant to the effects of insulin. This occurs when insulin levels are sufficiently high over a prolonged period of time, causing the body’s own sensitivity to the hormone to be reduced. Symptoms include lethargy, hunger, difficulty concentrating, and high blood pressure. Predisposing factors include obesity and hypertension. The Insulin Resistance...
-
Product Insights
Methylmalonic Acidemia - Drugs In Development, 2024
Empower your strategies with our Methylmalonic Acidemia – Drugs In Development, 2024 report and make more profitable business decisions. Methylmalonic Acidemia is an inborn or inherited metabolic disease where the levels of MMA (methylmalonic acid) are elevated in blood and urine. Deficiency in MMA Defect in conversion of methylmalonyl-coenzyme A (CoA) to succinyl-CoA causes accumulation of methylmalonyl-CoA and other potentially toxic compounds. It can be mild to severe appearing in early stages of life or in later stages. Seizures, encephalopathy and...
-
Product Insights
Mixed Dyslipidemia - Drugs In Development, 2024
Empower your strategies with our Mixed Dyslipidemia – Drugs In Development, 2024 report and make more profitable business decisions. Dyslipidemia is a condition where the lipid levels in blood are either low or high. While in mixed dyslipidemia the levels of LDL (low density lipoprotein) and TG (triglycerides) are elevated, and HDL (high density lipoprotein) is low. This occurs when there is an overproduction of very low-density lipoprotein (VLDL) leading to an increase in LDL and TG. People with mixed dyslipidemia...
-
Product Insights
Familial Amyloid Cardiomyopathy - Drugs In Development, 2024
Empower your strategies with our Familial Amyloid Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions. Familial amyloid cardiomyopathy (FAC), or transthyretin amyloid cardiomyopathy (ATTR-CM), results from the aggregation and deposition of mutant and wild-type transthyretin (TTR) protein in the heart. TTR is usually circulated as a homo-tetramer; however, in FAC patients, TTR dissociates and misassembles into amyloid fibrils that are insoluble and resistant to degradation. Due to this resistance to degradation, when amyloid fibrils accumulate in...
-
Product Insights
Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Drugs In Development, 2024
Empower your strategies with our Familial Chylomicronemia (Type I Hyperlipoproteinemia) – Drugs In Development, 2024 report and make more profitable business decisions. Familial chylomicronemia syndrome (hyperlipoproteinemia type 1) is an inherited condition that disrupts the breakdown of fats in the body, causing high levels of fat to build up in the blood. It is characterized by pancreatitis, abdominal pain, enlargement of the liver and spleen (hepatosplenomegaly), and small yellow skin lesions called eruptive xanthomas. Familial chylomicronemia syndrome is caused by genetic...
-
Product Insights
Heredofamilial Amyloidosis - Drugs In Development, 2024
Empower your strategies with our Heredofamilial Amyloidosis – Drugs In Development, 2024 report and make more profitable business decisions. Heredofamilial Amyloidosis refers to a group of inherited disorders characterized by the deposition of abnormal amyloid proteins in tissues and organs throughout the body. Amyloidosis occurs when certain proteins misfold and aggregate, forming insoluble fibrils that can accumulate in organs and tissues, disrupting their normal function. The term "heredofamilial" indicates that these conditions have a genetic basis and can be inherited to...
-
Product Insights
Propionic Acidemia - Drugs In Development, 2024
Empower your strategies with our Propionic Acidemia – Drugs In Development, 2024 report and make more profitable business decisions. The spectrum of propionic acidemia (PA) ranges from neonatal-onset to late-onset disease. Neonatal-onset PA is characterized by a healthy newborn with poor feeding and decreased arousal in the first few days of life, followed by progressive encephalopathy of unexplained origin. Without prompt diagnosis, this is followed by progressive encephalopathy manifesting as lethargy, seizures, or coma that can result in death. Individuals with...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.